MPP-Home

en / fr

Using our successes to build a broader future – an end of year message from Charles Gore

Charles Gore reflects on his first months as MPP Executive Director and looks ahead to a broader role for the MPP.

The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir

The licence will enable quality-assured manufacturers to develop and sell generic medicines containing G/P in low- and middle-income countries at affordable prices, enabling access to and treatment scale-up with the most effective pan-genotypic regimens.

The Medicines Patent Pool Presents New Five-Year Strategy For Improving Access To Priority Treatments In Developing Countries

Strategy and Related Feasibility Study Call for the Expansion of the MPP’s Mandate to Patented Medicines on the World Health Organization’s Model List of Essential Medicines

Exploring The Expansion Of The Medicines Patent Pool’s Mandate To Patented Essential Medicines

A Feasibility Study Of The Public Health Needs And Potential Impact

Who We Are

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.

Vision & Mission

Our Model

Strategy

Governance & Team

Funding

Who We Work With

MedsPaL

The Medicines Patents & Licences Database

The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.

Additional information and disclaimers

Transparency

All MPP licences are publicly available in their entirety on our website. This is unprecedented in the pharmaceutical field.

Licence Overview

Update on Progress of Sublicensees

Projections

Projections Tool

MPP in Numbers

Hover over the numbers to find out more

9 patent holders with MPP signed agreements

17 million patient-years through MPP’s generic partners from January 2012 to December 2017

24 generic manufacturers and product developers sublicensed from the MPP

18 products licensed to the MPP

130+

130+ ongoing pharmaceutical development projects

87% to 91%

87% to 91% of people living with HIV in developing countries covered by the MPP adult licences

92 to 131

92 to 131 countries covered by MPP adults licences

553

553 million dollars saved, from January 2012 to December 2017

Latest News

15 January 2019

The Medicines Patent Pool Governance Board appoints Mo Barry as new member for community interests

Geneva, 15 January 2019 - The Medicines Patent Pool (MPP) Governance Board has appointed Mohammed (Mo) Barry, as its newest and, at just 27-years-old, its youngest member. Mo is a global health champion and advocate from The Gambia. He brings to this position experience of a wide-range of governance roles in the field of infectious diseases. He is a United Nations Young Ambassador for the Sustainable Development Goals; Chairperson of the HIV Young Leaders Fund; Co-Chair of UNAIDS PACT, a global youth consortium on HIV; and a One Young World Ambassador. Prior to this, he worked for UNAIDS in Myanmar; supported policy research at the West Africa Civil Society Institute in Ghana; served on the International Treatment Preparedness Coalition World Community Advisory Board; Co-Chaired the Youth and Community Programme of the 20th International AIDS Conference in Australia and served on the board of the West Africa Treatment Action Group, monitoring access to HIV and tuberculosis treatment in 15 West African c...

09 January 2019

The Medicines Patent Pool welcomes findings of crucial Lancet Commission into accelerating elimination of viral hepatitis

Geneva, 9 January 2019. The Medicines Patent Pool (MPP) today congratulated The Lancet Gastroenterology & Hepatology Journal for its comprehensive study into the global impact of viral hepatitis. The report is the result of an expert Commission, convened two years ago to look at the current scale of the epidemic and how to accelerate its elimination. The key finding is that, while the global aim to eliminate viral hepatitis by 2030 is ambitious, it is achievable. Charles Gore, Executive Director at the MPP, and Liudmyla Maistat from the MPP’s policy team were part of the Commission, which highlights the importance of MPP’s role in reducing prices through public health licences with originator companies to provide affordable access in low- and middle-income countries (LMICs). MPP has licences for daclatasvir with Bristol-Myers Squibb and for glecaprevir/pibrentasvir with AbbVie for the treatment of hepatitis C and for tenofovir alafenamide with Gilead for the treatment of hepatitis B. As the report poin...

12 December 2018

The Medicines Patent Pool and Unitaid publish intellectual property report on long-acting technologies

Geneva, 12 December 2018: The Medicines Patent Pool (MPP) and Unitaid have jointly published a study into the patent landscape for the long-acting technologies that could have major impact for preventing or treating major diseases in low- and middle-income countries. The report can be accessed here. The report provides an overview of the intellectual property status of long-acting products for major diseases that are under development or already on the market. Specifically, the report finds that the patent situation for long-acting products can be complex, with patent protection on the drugs themselves, on the technologies needed to manufacture them, and, in some cases, on the delivery devices. In the case of nanoformulations for example, there is high potential for multiple overlapping patents. The delivery platforms are often applied to multiple products and are covered as well by extensive intellectual property protection. The above complexity, as well as other factors summarised in the report, may...

Videos

Unable to load video, please allow cookie

Endorsements

“Two billion people worldwide lack access to life-changing treatments – including medicines, vaccines and diagnostic tools. Wellcome spends around £1 billion each year to support research and drive reform to improve health for people around the world. The f...”

Unable to load twitter timeline, please allow cookie